

64. Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. *World J Gastroenterol* 2018; 24(19):2047-2060. doi: 10.3748/wjg.v24.i19.2047.
65. Okaniwa S. How Does Ultrasound Manage Pancreatic Diseases? *Ultrasound Findings and Scanning Maneuvers. Gut Liver* 2020; 14(1):37-46. doi: 10.5009/gnl18567.
66. Kanno A, Masamune A, Hanada K, et al. Multicenter study of early pancreatic cancer in Japan. *Pancreatol* 2018; 18(1):61-67. doi: 10.1016/j.pan.2017.11.007.
67. Chu LC, Park S, Kawamoto S, et al. Pancreatic Cancer Imaging: A New Look at an Old Problem. *Curr Probl Diagn Radiol* 2021; 50(4):540-550. doi: 10.1067/j.cpradiol.2020.08.002.
68. Jutric Z, Melstrom LG. New Treatment Options and Management Considerations in Borderline Resectable Pancreatic Cancer. *Oncology (Williston Park)* 2017; 31(6):443-52.
69. Joo I, Lee JM, Lee ES, et al. Preoperative CT Classification of the Resectability of Pancreatic Cancer: Interobserver Agreement. *Radiology* 2019; 293(2):343-349. doi: 10.1148/radiol.2019190422.
70. Hong SB, Lee SS, Kim JH, et al. Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria. *Radiology* 2018; 289(3):710-718. doi: 10.1148/radiol.2018180628.
71. Shen YN, Bai XL, Li GG, Liang TB. Review of radiological classifications of pancreatic cancer with peripancreatic vessel invasion: are new grading criteria required? *Cancer Imaging* 2017; 17(1):14. doi: 10.1186/s40644-017-0115-7.
72. Pietryga JA, Morgan DE. Imaging preoperatively for pancreatic adenocarcinoma. *J Gastrointest Oncol* 2015; 6(4):343-57. doi: 10.3978/j.issn.2078-6891.2015.024.
73. Elbanna KY, Jang HJ, Kim TK. Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review. *Insights Imaging* 2020; 11(1):58. doi: 10.1186/s13244-020-00861-y.
74. Blouhos K, Boulas KA, Tsalis K, Hatzigeorgiadis A. The isoattenuating pancreatic adenocarcinoma: Review of the literature and critical analysis. *Surg Oncol* 2015; 24(4):322-8. doi: 10.1016/j.suronc.2015.09.006.
75. Psar R, Urban O, Cerna M, et al. Improvement of the Diagnosis of Isoattenuating Pancreatic Carcinomas by Defining their Characteristics on Contrast Enhanced Computed Tomography and Endosonography with Fine-Needle Aspiration (EUS-FNA). *Diagnostics (Basel)* 2021; 11(5):776. doi: 10.3390/diagnostics11050776.
76. Kobashi Y, Uchiyama M, Matsui J. The „K-Sign“-A Novel CT Finding Suggestive before the Appearance of Pancreatic Cancer. *Cancers (Basel)* 2021; 13(16):4222. doi: 10.3390/cancers13164222.
77. Yamao K, Tsurusaki M, Takashima K, et al. Analysis of Progression Time in Pancreatic Cancer including Carcinoma In Situ Based on Magnetic Resonance Cholangiopancreatography Findings. *Diagnostics (Basel)* 2021; 11(10):1858. doi: 10.3390/diagnostics11101858.
78. Scheufele F, Schorn S, Demir IE, et al. Preoperative biliary stenting versus operation first in jaundiced patients due to malignant lesions in the pancreatic head: A meta-analysis of current literature. *Surgery* 2017; 161(4):939-950. doi: 10.1016/j.surg.2016.11.001.
79. DeWitt J, Devereaux B, Chriswell M, et al. Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer. *Ann Intern Med* 2004; 141(10):753-63. doi: 10.7326/0003-4819-141-10-200411160-00006.
80. Kitano M, Yoshida T, Itonaga M, et al. Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer. *J Gastroenterol* 2019; 54(1):19-32. doi: 10.1007/s00535-018-1519-2.
81. Săftoiu A, Vilman P. Role of endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. *J Clin Ultrasound* 2009; 37(1):1-17. doi: 10.1002/jcu.20534.
82. Klapman JB, Chang KJ, Lee JG, Nguyen P. Negative predictive value of endoscopic ultrasound in a large series of patients with a clinical suspicion of pancreatic cancer. *Am J Gastroenterol* 2005; 100(12):2658-61. doi: 10.1111/j.1572-0241.2005.00315.x.
83. Puli SR, Singh S, Hagedorn CH, et al. Diagnostic accuracy of EUS for vascular invasion in pancreatic and periampullary cancers: a meta-analysis and systematic review. *Gastrointest Endosc* 2007; 65(6):788-97. doi: 10.1016/j.gie.2006.08.028.
84. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. *N Engl J Med* 2018; 379(25):2395-2406. doi: 10.1056/NEJMoa1809775.
85. Versteijne E, Suker M, Groothuis K, et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. *J Clin Oncol* 2020; 38(16):1763-1773. doi: 10.1200/JCO.19.02274.
86. Hackert T, Sachsenmaier M, Hinz U, et al. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With FOLFIRINOX Results in Resectability in 60% of the Patients. *Ann Surg* 2016; 264(3):457-463. doi: 10.1097/SLA.0000000000001850.
87. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2021; 19(4):439-457. doi:10.6004/jnccn.2021.0017.
88. Gränsmark E, Bågenholm Bylin N, Blomstrand H, et al. Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer. *Front Oncol* 2020; 10:1176. doi:10.3389/fonc.2020.01176.
89. Golan T, Hammel P, Reni M, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *N Engl J Med* 2019; 381(4):317-327. doi:10.1056/NEJMoa1903387.
90. Leroux C, Konstantinidou G. Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology. *Cancers (Basel)* 2021; 13(4):799. doi:10.3390/cancers13040799.

ON-LINE KURZ

On-line kurz Kardiovaskulární onemocnění

2

PŘEDNÁŠKY

- **Léčba hypertenze v roce 2022? Cílem je snížit riziko kardiovaskulární příhody!** – MUDr. Petra Vysočanová
- **Dušnost** – MUDr. Marek Šramko, Ph.D.
- **Bolest na hrudi** – doc. MUDr. Jiří Kettner, CSc.
- **Palpitace** – prof. MUDr. Josef Kautzner, CSc., FESC
- **Synkopy** – MUDr. Jana Hašková

POČET
KREDITŮ **2**

Registrace
ZDARMA

TERMÍN

květen 2022
až květen 2023

dostupný na
online.solen.cz

ODBORNÝ GARANT

MUDr. Petra Vysočanová
Fakultní nemocnice Brno-Bohunice,
Interní kardiologická klinika



KONTAKT: Mgr. Vendula Pávková
+420 777 714 679 | pavkova@solen.cz



PARTNER

